Neuronetics Inc
$ 1.94
14.12%
30 Apr - close price
- Market Cap 134,984,000 USD
- Current Price $ 1.94
- High / Low $ 1.96 / 1.68
- Stock P/E N/A
- Book Value 0.32
- EPS -0.59
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -1.35 %
- 52 Week High 4.85
- 52 Week Low 0.80
About
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$4.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-17 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-04 | 2024-11-05 | 2024-08-12 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.1 | -0.13 | -0.15 | -0.2062 | -0.33 | -0.4408 | -0.33 | -0.27 | -0.19 | -0.33 | -0.17 | -0.38 |
| Estimated EPS | -0.0922 | -0.13 | -0.08 | -0.1167 | -0.24 | -0.23 | -0.27 | -0.31 | -0.26 | -0.31 | -0.35 | -0.39 |
| Surprise | -0.0078 | 0 | -0.07 | -0.0895 | -0.09 | -0.2108 | -0.06 | 0.04 | 0.07 | -0.02 | 0.18 | 0.01 |
| Surprise Percentage | -8.4599% | 0% | -87.5% | -76.6924% | -37.5% | -91.6522% | -22.2222% | 12.9032% | 26.9231% | -6.4516% | 51.4286% | 2.5641% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: STIM
2026-04-30 02:09:15
This page on Stock Titan offers a comprehensive resource for Neuronetics (STIM) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights how Neuronetics, a medical technology company focusing on NeuroStar Advanced Therapy and Greenbrook TMS treatment centers, reports its financial performance, capital structure, and risks. The article also provides summaries of recent filings, including insider transactions, leadership changes, and financial results.
2026-04-29 21:09:15
Neuronetics, Inc. announced inducement awards granted to six new non-executive employees under Nasdaq Listing Rule 5635(c)(4). These awards, primarily Restricted Stock Units (RSUs), were approved by the Compensation Committee as a material inducement for their employment. The vesting of these awards is contingent upon the employees' continued service with the company through the specified vesting dates.
2026-04-28 06:10:20
Neuronetics, Inc. (NASDAQ: STIM) is set to announce its first-quarter 2026 financial results before market open on Tuesday, May 5, 2026, followed by a conference call at 8:30 a.m. Eastern Time. The company, known for its NeuroStar Advanced Therapy system for neurohealth disorders and operating Greenbrook TMS Inc. centers, will provide webcast access for interested participants. The NeuroStar system has FDA clearance for major depressive disorder, obsessive-compulsive disorder, and adolescent patients with depression.
2026-04-27 03:09:17
This article mentions Neuronetics is projecting Q4 revenue between $40 million and $43 million. This outlook is attributed to the product mix, including SPRAVATO. The Q4 performance is expected to influence the full-year financial results for the company.
2026-04-26 23:09:17
This article reports a significant increase in Neuronetics' (STIM) price target, which has risen by 44.44% to $4.42. This upward adjustment suggests a positive outlook from analysts regarding the company's future stock performance.
2026-04-23 02:08:56
Jorey Chernett, a major shareholder in Neuronetics (NASDAQ:STIM), recently purchased 100,000 shares of the company's stock for $158,000, bringing his total direct ownership to approximately 9.88 million shares. This follows several other significant buys in March, accumulating roughly 1.86 million insider shares. Following the news, STIM shares rose by 5.7% to $1.59, and analysts currently hold a "Hold" rating with an average target price of $3.00.
